| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/17/2008 | WO2007084853A3 Methods for inhibiting osteoclastogenesis |
| 01/17/2008 | WO2007084728A3 2-imino-benzimidazoles |
| 01/17/2008 | WO2007084413B1 Methods for treating hepatitis c |
| 01/17/2008 | WO2007081974A3 Viral hepatitis treatment |
| 01/17/2008 | WO2007081907A3 Crystalline forms of dolasetron base and processes for preparation thereof |
| 01/17/2008 | WO2007079139A3 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 01/17/2008 | WO2007075883A3 Transdermal delivery of meptazinol |
| 01/17/2008 | WO2007075297A3 Muscarinic agonists and methods of use thereof |
| 01/17/2008 | WO2007074078A3 Aryl-isoxazol-4-yl-imidazole derivatives |
| 01/17/2008 | WO2007067341A3 Compositions and methods for increasing insulin sensitivity |
| 01/17/2008 | WO2007066187A3 Method of treating abnormal cell growth |
| 01/17/2008 | WO2007064759A3 Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain |
| 01/17/2008 | WO2007063428A3 Pharmaceutical compositions comprising carboxyalkylsulfonic acids |
| 01/17/2008 | WO2007062318A3 Chemical compounds |
| 01/17/2008 | WO2007062190A3 Chemical compounds |
| 01/17/2008 | WO2007056335A3 Methods of sensitizing cancer to therapy-induced cytotoxicity |
| 01/17/2008 | WO2007056300A3 Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| 01/17/2008 | WO2007053696A3 Rnai inhibition of influenza virus replication |
| 01/17/2008 | WO2007048645A3 Protection of oxidizable agents |
| 01/17/2008 | WO2007021938A3 Method of enhancing therapeutic effect of nucleic acids |
| 01/17/2008 | WO2007019080A3 Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
| 01/17/2008 | WO2007016476A3 Hepatitis c serine protease inhibitors and uses therefor |
| 01/17/2008 | WO2007008769A3 Use of pseudan and pseudan inclusion bodies |
| 01/17/2008 | WO2007005838A3 Hcv inhibitors |
| 01/17/2008 | WO2007005534A8 Chemical compounds |
| 01/17/2008 | WO2006137789A8 Quinoline 3 -sulfonate esters as NK3 receptor modulators |
| 01/17/2008 | WO2006116322A3 Nicotinamide riboside kinase compositions and methods for using the same |
| 01/17/2008 | WO2006113505A3 Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| 01/17/2008 | WO2006060809A9 Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
| 01/17/2008 | WO2006056930A3 Novel 4 -aminopiperidine derivatives as plasmepsin ii inhibitors |
| 01/17/2008 | WO2006052880A3 Synergistic effects of combined administration of mirtazapine and a stimulant compound |
| 01/17/2008 | WO2006034048A3 Therapeutic agents targeting the ncca-atp channel and methods of use thereof |
| 01/17/2008 | WO2005065667A3 Compositions for treating or preventing obesity and insulin resistance disorders |
| 01/17/2008 | WO2004072257A3 Dyrks as modifiers of the apc and axin pathways and methods of use |
| 01/17/2008 | WO2002053187A3 Methods and transdermal compositions for pain relief |
| 01/17/2008 | WO2001082875A3 A core formulation |
| 01/17/2008 | US20080015700 Spine distraction implant and method |
| 01/17/2008 | US20080015359 Process for the Preparation of Telmisartan |
| 01/17/2008 | US20080015350 Used in the manufacture of other forms of beta-L-2'-deoxythymidine (telbivudine); increased solubility, improved bioavailability, ease of chemical processing and/or ease of pharmaceutical formulation; hepatitis B |
| 01/17/2008 | US20080015343 Azithromycin dosage forms with reduced side effects |
| 01/17/2008 | US20080015265 Methods of treating obesity using satiety factors |
| 01/17/2008 | US20080015261 Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function |
| 01/17/2008 | US20080015260 Pharmaceutical compositions having improved stability and methods for preparation and use |
| 01/17/2008 | US20080015259 Substantially pure O-desmethylvenlafaxine and processes for preparing it |
| 01/17/2008 | US20080015258 Dissolving moprolol and tartaric acid in a 2:1 molar ratio in ethanol, precipitating and filtering; gels ointments, eyedrops; glaucoma; improved tolerability over hydrochloride salt |
| 01/17/2008 | US20080015257 Compositions and methods for reducing body fat |
| 01/17/2008 | US20080015256 Tetralin and indane derivatives and uses thereof |
| 01/17/2008 | US20080015255 Pharmaceutical Compositions Based on Fluorinated Sulphamides and Sulphinimides |
| 01/17/2008 | US20080015254 5-[3-(2,6-Dimethylbenzyloxy)-phenyl]-pent-4-enoic acid ethyl ester; insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis, arteriosclerosis; side effects reduction; orally active |
| 01/17/2008 | US20080015253 Peroxisome Proliferator Activated Receptors modulators; ethyl (R,S)-2-(4-trifluoromethylphenyl)oxypent-4-enoate; dyslipidemia, atherosclerosis and diabetes |
| 01/17/2008 | US20080015252 Therapeutic agent for virus-associated malignancy |
| 01/17/2008 | US20080015251 Means and method for treating lipotoxicity and other metabolically related phenomena |
| 01/17/2008 | US20080015250 Ultraviolet absorbing ophthalmic compositions |
| 01/17/2008 | US20080015249 Cancer treatment compositions and method using natural plant essential oils |
| 01/17/2008 | US20080015248 synthetic tea derived flavonoids, used for the of treatment of cancers; anticarcinogenic agents; enzyme inhibitors |
| 01/17/2008 | US20080015247 quercetin, vitamin B3, and vitamin C as only ingredients, specified weight ratio; dietary supplement or a pharmaceutical formulation; free radical induced diseases |
| 01/17/2008 | US20080015246 Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof |
| 01/17/2008 | US20080015245 1,5-diarylpyrrole derivatives, preparation method thereof and application of same in therapeutics |
| 01/17/2008 | US20080015243 Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| 01/17/2008 | US20080015242 Use of N-[3-[2-[2-(3-methylindazol-6-yloxy)ethylamino]-1-hydroxyethyl]phenyl]methanesulfonamide or salt for treating diabetes, obesity, hyperlipidemia and urinary incontinence; drug interaction side effect reduction |
| 01/17/2008 | US20080015241 All day rhinitic condition treatment regimen |
| 01/17/2008 | US20080015240 Acid Salt of Benzimidazole Derivative and Crystal Thereof |
| 01/17/2008 | US20080015239 For glaucoma or ocular hypertension, irritable bowel disease, and maintenance of colonic mucous |
| 01/17/2008 | US20080015238 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals |
| 01/17/2008 | US20080015237 New compounds i/418 |
| 01/17/2008 | US20080015236 Method for promoting myocardial regeneration and uses thereof |
| 01/17/2008 | US20080015235 Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses |
| 01/17/2008 | US20080015234 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 01/17/2008 | US20080015233 2,4,6-Substituted Pyridyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease |
| 01/17/2008 | US20080015232 Schweinfurthin analogues |
| 01/17/2008 | US20080015231 Therapeutic compounds |
| 01/17/2008 | US20080015230 Heterocyclic derivatives and their use as therapeutic agents |
| 01/17/2008 | US20080015229 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes |
| 01/17/2008 | US20080015228 Use of a pyrazole derivative for preparing medicines useful for preventing or treating renal diseases |
| 01/17/2008 | US20080015227 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
| 01/17/2008 | US20080015226 Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors |
| 01/17/2008 | US20080015225 Dimeric Piperidine Derivatives |
| 01/17/2008 | US20080015224 Nitroxide superoxide dismutase mimetics to treat extracellular superoxide dismutase deficiencies |
| 01/17/2008 | US20080015223 Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto |
| 01/17/2008 | US20080015222 New Heterocyclic Amides |
| 01/17/2008 | US20080015221 Compound capable of cytoskeleton and induction of cell elongation and process for synthesizing the same |
| 01/17/2008 | US20080015220 Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma |
| 01/17/2008 | US20080015219 Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds |
| 01/17/2008 | US20080015218 Antioxidant combinations for use in ruminant feed rations having a fat source |
| 01/17/2008 | US20080015217 Antioxidant combinations for use in ruminant feed rations |
| 01/17/2008 | US20080015216 Histone Deacetylase Inhibitors |
| 01/17/2008 | US20080015215 Diamine derivatives |
| 01/17/2008 | US20080015214 3-piperidin-4-yl-indole orl-1 receptor modulators |
| 01/17/2008 | US20080015213 Macrocyclic Aminopyridyl Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease |
| 01/17/2008 | US20080015212 Inhibitors Of Akt Activity |
| 01/17/2008 | US20080015211 Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists |
| 01/17/2008 | US20080015210 Base-Stabilized Polyorthoester Formulations |
| 01/17/2008 | US20080015209 Compounds for the treatment of metabolic disorders |
| 01/17/2008 | US20080015208 3-Fluoro-N-(5-ureidomethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-benzenesulfonamide; serotonin receptors 5-HT6 and 5-HT2A ligand; neurodegenerative disorders; antidepressant, anxiolytic agent; Parkinson's disease, Huntington's disease, manic depression, psychoses, epilepsy, obesity, drug abuse |
| 01/17/2008 | US20080015207 administering a therapeutic amount of DL3 (6-amino-2-(2-4-tert-butyl-phenoxy)-ethylsulfanyl)-1H-pyrimidin-4-one) to a patient for treating prostate cancer, benign prostatic hyperplasia, hair loss |
| 01/17/2008 | US20080015206 Anti-cancer cyclopenta[G]quinazoline compounds |
| 01/17/2008 | US20080015205 Cancer Combination Therapy Comprising Azd2171 and Imatinib |
| 01/17/2008 | US20080015204 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 01/17/2008 | US20080015203 Such as 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide; glucokinases (Glk) |
| 01/17/2008 | US20080015202 Thiazole Derivatives Having Vap-1 Inhibitory Activity |